Electrotherapy medical device maker Zynex has received US Food and Drug Administration (FDA) clearance for its NexWave device.

The NexWave device is capable of delivering three modalities of stimulation: transcutaneous electrical nerve stimulation, interferential electrical stimulation and neuromuscular electrical stimulation.

Zynex CEO Thomas Sandgaard said that the combined modalities of the company’s NexWave provide doctors and clinicians a comprehensive pain therapy solution for their patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

”We believe this new product is unique in the electrotherapy industry and provides our sales force with a competitive edge to fuel revenue generation in our already rapidly growing Zynex Medical subsidiary," Sandgaard added.

See Also: